Immunogenicity of the Inactivated SARS-CoV-2 Vaccine (BBIBP-CorV) in Hemodialysis Patients: A Case-Control Study
-
Soroush Khojasteh-Kaffash
,
Reza Jafari
,
Alireza Fereidouni
,
Ali Fanoodi
,
Vajehallah Raeesi
,
Mahsa Najafzadeh
,
Mohammad Fereidouni
Abstract
Background/objectives: Studies have shown that immune responses to COVID-19 vaccines are impaired in dialysis patients which may affect immunity to vaccines. Therefore, this study aimed to evaluate SARS-COV-2 neutralizing antibodies in hemodialysis patients for 2 and 6 weeks after receiving inactivated Sinopharm vaccine.
Methods: In this study, 172 people were divided into two groups. The first group included 108 hemodialysis patients, while the second group included 64 health workers as a control group. In order to evaluate SARS-COV-2 neutralizing antibodies titers, the peripheral blood samples were collected from all participants 2 and 6 weeks after receiving the second dose of Sinopharm vaccine. Samples were centrifuged and the neutralizing antibody against receptor-binding domain (RBD) was determined using the indirect ELISA technique.
Results: Hemodialysis patients had lower titers of IgG neutralizing antibodies compared to the control group (P <0.001). The titers of SARS-COV-2 neutralizing antibodies were not significantly different at 2 weeks in comparison with 6 weeks after vaccination (P=0.9204). Our findings showed a significant increase in titers of IgG neutralizing antibodies after vaccination in people with a history of COVID-19 (P=0.002). The seropositivity rate for neutralizing antibodies against RBD was significantly different between seropositive (immune) and seronegative (non-immune) patients 6 weeks after vaccination (P=0.022).
Conclusions: The titers of neutralizing antibodies against SARS-COV-2 were lower in hemodialysis patients than in healthy individuals. This is probably due to the poor immune system. However, patients who received two doses of inactivated Sinopharm vaccine showed a higher antibody titer 6 weeks after vaccination.
1. Navayi M, Fanoodi A, Salmani F, Abedi F, Shetty S, Riahi SMJPH. Over 60 years of age as an independent prognostic factor of in-hospital mortality among COVID-19 patients: a cohort study in an Iranian high-incidence area. 2021;200:33-8.
2. Tsukuda S, Watashi K. Hepatitis B virus biology and life cycle. Antiviral research. 2020;182:104925.
3. Chen N, Zhou M, Dong X, Qu J, Gong F, Han Y, et al. Epidemiological and clinical characteristics of 99 cases of 2019 novel coronavirus pneumonia in Wuhan, China: a descriptive study. Lancet (London, England). 2020;395(10223):507-13.
4. Qin C, Zhou L, Hu Z, Zhang S, Yang S, Tao Y, et al. Dysregulation of Immune Response in Patients With Coronavirus 2019 (COVID-19) in Wuhan, China. Clinical infectious diseases: an official publication of the Infectious Diseases Society of America. 2020;71(15):762-8.
5. Chung EYM, Palmer SC, Natale P, Krishnan A, Cooper TE, Saglimbene VM, et al. Incidence and Outcomes of COVID-19 in People With CKD: A Systematic Review and Meta-analysis. American journal of kidney diseases : the official journal of the National Kidney Foundation. 2021;78(6):804-15.
6. Hilbrands LB, Duivenvoorden R, Vart P, Franssen CFM, Hemmelder MH, Jager KJ, et al. COVID-19-related mortality in kidney transplant and dialysis patients: results of the ERACODA collaboration. Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association. 2020;35(11):1973-83.
7. Hsu CM, Weiner DE, Aweh G, Miskulin DC, Manley HJ, Stewart C, et al. COVID-19 Among US Dialysis Patients: Risk Factors and Outcomes From a National Dialysis Provider. American journal of kidney diseases : the official journal of the National Kidney Foundation. 2021;77(5):748-56.e1.
8. Kikuchi K, Nangaku M, Ryuzaki M, Yamakawa T, Hanafusa N, Sakai K, et al. COVID-19 of dialysis patients in Japan: Current status and guidance on preventive measures. Therapeutic apheresis and dialysis : official peer-reviewed journal of the International Society for Apheresis, the Japanese Society for Apheresis, the Japanese Society for Dialysis Therapy. 2020;24(4):361-5.
9. Yen JS, Wang IK, Yen TH. COVID-19 vaccination and dialysis patients: why the variable response. QJM : monthly journal of the Association of Physicians. 2021;114(7):440-4.
10. Forni G, Mantovani AJCD, Differentiation. COVID-19 vaccines: where we stand and challenges ahead. 2021;28(2):626-39.
11. Polack FP, Thomas SJ, Kitchin N, Absalon J, Gurtman A, Lockhart S, et al. Safety and efficacy of the BNT162b2 mRNA Covid-19 vaccine. 2020.
12. Voysey M, Clemens SAC, Madhi SA, Weckx LY, Folegatti PM, Aley PK, et al. Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK. Lancet (London, England). 2021;397(10269):99-111.
13. Logunov DY, Dolzhikova IV, Shcheblyakov DV, Tukhvatulin AI, Zubkova OV, Dzharullaeva AS, et al. Safety and efficacy of an rAd26 and rAd5 vector-based heterologous prime-boost COVID-19 vaccine: an interim analysis of a randomised controlled phase 3 trial in Russia. 2021;397(10275):671-81.
14. Beijing Institute of Biological Products Co. L. Recommendation for an Emergency Use Listing of COVID-19 Vaccine BIBP 2021 [Available from: https://extranet.who.int/pqweb/file/4960602/download.
15. Wang H, Zhang Y, Huang B, Deng W, Quan Y, Wang W, et al. Development of an Inactivated Vaccine Candidate, BBIBP-CorV, with Potent Protection against SARS-CoV-2. Cell. 2020;182(3):713-21.e9.
16. Gharate JS, Daitkar SA, Aher KA. Approved COVID 19 Vaccines: a Review. World Journal of Pharmaceutical Research. 2021;10(10):523-42.
17. Neutralizing antibody: Biology-Online; 2021 [cited 5 July 2021]. Available from: https://www.biologyonline.com/dictionary/Neutralizing_antibody.
18. Khoury DS, Cromer D, Reynaldi A, Schlub TE, Wheatley AK, Juno JA, et al. Neutralizing antibody levels are highly predictive of immune protection from symptomatic SARS-CoV-2 infection. Nature medicine. 2021.
19. Mercado NB, Zahn R, Wegmann F, Loos C, Chandrashekar A, Yu J, et al. Single-shot Ad26 vaccine protects against SARS-CoV-2 in rhesus macaques. Nature. 2020;586(7830):583-8.
20. Güzel E, Çelikkol A, Erdal B, Sedef N. Immunogenicity after CoronaVac vaccination. Revista da Associacao Medica Brasileira (1992). 2021;67(10):1403-8.
21. Erol Ç, Yanık Yalçın T, Sarı N, Bayraktar N, Ayvazoğlu Soy E, Yavuz Çolak M, et al. Differences in Antibody Responses Between an Inactivated SARS-CoV-2 Vaccine and the BNT162b2 mRNA Vaccine in Solid-Organ Transplant Recipients. Experimental and clinical transplantation : official journal of the Middle East Society for Organ Transplantation. 2021;19(12):1334-40.
22. Rogers TF, Zhao F, Huang D, Beutler N, Burns A, He W-T, et al. Isolation of potent SARS-CoV-2 neutralizing antibodies and protection from disease in a small animal model. Science. 2020;369(6506):956-63.
23. Torreggiani M, Blanchi S, Fois A, Fessi H, Piccoli GB. Neutralizing SARS-CoV-2 antibody response in dialysis patients after the first dose of the BNT162b2 mRNA COVID-19 vaccine: the war is far from being won. Kidney Int. 2021;99(6):1494-6.
24. Windpessl M, Bruchfeld A, Anders HJ, Kramer H, Waldman M, Renia L, et al. COVID-19 vaccines and kidney disease. Nature reviews Nephrology. 2021;17(5):291-3.
25. Agur T, Ben-Dor N, Goldman S, Lichtenberg S, Herman-Edelstein M, Yahav D, et al. Antibody response to mRNA SARS-CoV-2 vaccine among dialysis patients - a prospectivecohort study. Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association. 2021.
26. Stumpf J, Siepmann T, Lindner T, Karger C, Schwöbel J, Anders L, et al. Humoral and cellular immunity to SARS-CoV-2 vaccination in renal transplant versus dialysis patients: A prospective, multicenter observational study using mRNA-1273 or BNT162b2 mRNA vaccine. The Lancet regional health Europe. 2021;9:100178.
27. Syed-Ahmed M, Narayanan M. Immune Dysfunction and Risk of Infection in Chronic Kidney Disease. Advances in chronic kidney disease. 2019;26(1):8-15.
28. Frantzen L, Cavaille G, Thibeaut S, El-Haik Y. Efficacy of the BNT162b2 mRNA Covid-19 Vaccine in a hemodialysis cohort. Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association. 2021.
29. Grupper A, Sharon N, Finn T, Cohen R, Israel M, Agbaria A, et al. Humoral Response to the Pfizer BNT162b2 Vaccine in Patients Undergoing Maintenance Hemodialysis. Clinical journal of the American Society of Nephrology : CJASN. 2021;16(7):1037-42.
30. Jahn M, Korth J, Dorsch O, Anastasiou OE, Sorge-Hädicke B, Tyczynski B, et al. Humoral Response to SARS-CoV-2-Vaccination with BNT162b2 (Pfizer-BioNTech) in Patients on Hemodialysis. Vaccines. 2021;9(4).
31. Simon B, Rubey H, Treipl A, Gromann M, Hemedi B, Zehetmayer S, et al. Haemodialysis patients show a highly diminished antibody response after COVID-19 mRNA vaccination compared with healthy controls. Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association. 2021;36(9):1709-16.
32. Chen Y, Yin S, Tong X, Tao Y, Ni J, Pan J, et al. Dynamic SARS-CoV-2-specific B-cell and T-cell responses following immunization with an inactivated COVID-19 vaccine. Clinical Microbiology and Infection. 2022;28(3):410-8.
33. Marciani DJ. Vaccine adjuvants: role and mechanisms of action in vaccine immunogenicity. Drug Discovery Today. 2003;8(20):934-43.
34. Iavarone C, O’hagan DT, Yu D, Delahaye NF, Ulmer JB. Mechanism of action of mRNA-based vaccines. Expert Review of Vaccines. 2017;16(9):871-81.
35. He P, Zou Y, Hu Z. Advances in aluminum hydroxide-based adjuvant research and its mechanism. Human Vaccines & Immunotherapeutics. 2015;11(2):477-88.
36. Ariamanesh M, Porouhan P, PeyroShabany B, Fazilat-Panah D, Dehghani M, Nabavifard M, et al. Immunogenicity and Safety of the Inactivated SARS-CoV-2 Vaccine (BBIBP-CorV) in Patients with Malignancy. Cancer Investigation. 2022;40(1):26-34.
37. Petrović V, Vuković V, Patić A, Marković M, Ristić MJPo. Immunogenicity of BNT162b2, BBIBP-CorV and Gam-COVID-Vac vaccines and immunity after natural SARS-CoV-2 infection—A comparative study from Novi Sad, Serbia. 2022;17(2):e0263468.
2. Tsukuda S, Watashi K. Hepatitis B virus biology and life cycle. Antiviral research. 2020;182:104925.
3. Chen N, Zhou M, Dong X, Qu J, Gong F, Han Y, et al. Epidemiological and clinical characteristics of 99 cases of 2019 novel coronavirus pneumonia in Wuhan, China: a descriptive study. Lancet (London, England). 2020;395(10223):507-13.
4. Qin C, Zhou L, Hu Z, Zhang S, Yang S, Tao Y, et al. Dysregulation of Immune Response in Patients With Coronavirus 2019 (COVID-19) in Wuhan, China. Clinical infectious diseases: an official publication of the Infectious Diseases Society of America. 2020;71(15):762-8.
5. Chung EYM, Palmer SC, Natale P, Krishnan A, Cooper TE, Saglimbene VM, et al. Incidence and Outcomes of COVID-19 in People With CKD: A Systematic Review and Meta-analysis. American journal of kidney diseases : the official journal of the National Kidney Foundation. 2021;78(6):804-15.
6. Hilbrands LB, Duivenvoorden R, Vart P, Franssen CFM, Hemmelder MH, Jager KJ, et al. COVID-19-related mortality in kidney transplant and dialysis patients: results of the ERACODA collaboration. Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association. 2020;35(11):1973-83.
7. Hsu CM, Weiner DE, Aweh G, Miskulin DC, Manley HJ, Stewart C, et al. COVID-19 Among US Dialysis Patients: Risk Factors and Outcomes From a National Dialysis Provider. American journal of kidney diseases : the official journal of the National Kidney Foundation. 2021;77(5):748-56.e1.
8. Kikuchi K, Nangaku M, Ryuzaki M, Yamakawa T, Hanafusa N, Sakai K, et al. COVID-19 of dialysis patients in Japan: Current status and guidance on preventive measures. Therapeutic apheresis and dialysis : official peer-reviewed journal of the International Society for Apheresis, the Japanese Society for Apheresis, the Japanese Society for Dialysis Therapy. 2020;24(4):361-5.
9. Yen JS, Wang IK, Yen TH. COVID-19 vaccination and dialysis patients: why the variable response. QJM : monthly journal of the Association of Physicians. 2021;114(7):440-4.
10. Forni G, Mantovani AJCD, Differentiation. COVID-19 vaccines: where we stand and challenges ahead. 2021;28(2):626-39.
11. Polack FP, Thomas SJ, Kitchin N, Absalon J, Gurtman A, Lockhart S, et al. Safety and efficacy of the BNT162b2 mRNA Covid-19 vaccine. 2020.
12. Voysey M, Clemens SAC, Madhi SA, Weckx LY, Folegatti PM, Aley PK, et al. Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK. Lancet (London, England). 2021;397(10269):99-111.
13. Logunov DY, Dolzhikova IV, Shcheblyakov DV, Tukhvatulin AI, Zubkova OV, Dzharullaeva AS, et al. Safety and efficacy of an rAd26 and rAd5 vector-based heterologous prime-boost COVID-19 vaccine: an interim analysis of a randomised controlled phase 3 trial in Russia. 2021;397(10275):671-81.
14. Beijing Institute of Biological Products Co. L. Recommendation for an Emergency Use Listing of COVID-19 Vaccine BIBP 2021 [Available from: https://extranet.who.int/pqweb/file/4960602/download.
15. Wang H, Zhang Y, Huang B, Deng W, Quan Y, Wang W, et al. Development of an Inactivated Vaccine Candidate, BBIBP-CorV, with Potent Protection against SARS-CoV-2. Cell. 2020;182(3):713-21.e9.
16. Gharate JS, Daitkar SA, Aher KA. Approved COVID 19 Vaccines: a Review. World Journal of Pharmaceutical Research. 2021;10(10):523-42.
17. Neutralizing antibody: Biology-Online; 2021 [cited 5 July 2021]. Available from: https://www.biologyonline.com/dictionary/Neutralizing_antibody.
18. Khoury DS, Cromer D, Reynaldi A, Schlub TE, Wheatley AK, Juno JA, et al. Neutralizing antibody levels are highly predictive of immune protection from symptomatic SARS-CoV-2 infection. Nature medicine. 2021.
19. Mercado NB, Zahn R, Wegmann F, Loos C, Chandrashekar A, Yu J, et al. Single-shot Ad26 vaccine protects against SARS-CoV-2 in rhesus macaques. Nature. 2020;586(7830):583-8.
20. Güzel E, Çelikkol A, Erdal B, Sedef N. Immunogenicity after CoronaVac vaccination. Revista da Associacao Medica Brasileira (1992). 2021;67(10):1403-8.
21. Erol Ç, Yanık Yalçın T, Sarı N, Bayraktar N, Ayvazoğlu Soy E, Yavuz Çolak M, et al. Differences in Antibody Responses Between an Inactivated SARS-CoV-2 Vaccine and the BNT162b2 mRNA Vaccine in Solid-Organ Transplant Recipients. Experimental and clinical transplantation : official journal of the Middle East Society for Organ Transplantation. 2021;19(12):1334-40.
22. Rogers TF, Zhao F, Huang D, Beutler N, Burns A, He W-T, et al. Isolation of potent SARS-CoV-2 neutralizing antibodies and protection from disease in a small animal model. Science. 2020;369(6506):956-63.
23. Torreggiani M, Blanchi S, Fois A, Fessi H, Piccoli GB. Neutralizing SARS-CoV-2 antibody response in dialysis patients after the first dose of the BNT162b2 mRNA COVID-19 vaccine: the war is far from being won. Kidney Int. 2021;99(6):1494-6.
24. Windpessl M, Bruchfeld A, Anders HJ, Kramer H, Waldman M, Renia L, et al. COVID-19 vaccines and kidney disease. Nature reviews Nephrology. 2021;17(5):291-3.
25. Agur T, Ben-Dor N, Goldman S, Lichtenberg S, Herman-Edelstein M, Yahav D, et al. Antibody response to mRNA SARS-CoV-2 vaccine among dialysis patients - a prospectivecohort study. Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association. 2021.
26. Stumpf J, Siepmann T, Lindner T, Karger C, Schwöbel J, Anders L, et al. Humoral and cellular immunity to SARS-CoV-2 vaccination in renal transplant versus dialysis patients: A prospective, multicenter observational study using mRNA-1273 or BNT162b2 mRNA vaccine. The Lancet regional health Europe. 2021;9:100178.
27. Syed-Ahmed M, Narayanan M. Immune Dysfunction and Risk of Infection in Chronic Kidney Disease. Advances in chronic kidney disease. 2019;26(1):8-15.
28. Frantzen L, Cavaille G, Thibeaut S, El-Haik Y. Efficacy of the BNT162b2 mRNA Covid-19 Vaccine in a hemodialysis cohort. Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association. 2021.
29. Grupper A, Sharon N, Finn T, Cohen R, Israel M, Agbaria A, et al. Humoral Response to the Pfizer BNT162b2 Vaccine in Patients Undergoing Maintenance Hemodialysis. Clinical journal of the American Society of Nephrology : CJASN. 2021;16(7):1037-42.
30. Jahn M, Korth J, Dorsch O, Anastasiou OE, Sorge-Hädicke B, Tyczynski B, et al. Humoral Response to SARS-CoV-2-Vaccination with BNT162b2 (Pfizer-BioNTech) in Patients on Hemodialysis. Vaccines. 2021;9(4).
31. Simon B, Rubey H, Treipl A, Gromann M, Hemedi B, Zehetmayer S, et al. Haemodialysis patients show a highly diminished antibody response after COVID-19 mRNA vaccination compared with healthy controls. Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association. 2021;36(9):1709-16.
32. Chen Y, Yin S, Tong X, Tao Y, Ni J, Pan J, et al. Dynamic SARS-CoV-2-specific B-cell and T-cell responses following immunization with an inactivated COVID-19 vaccine. Clinical Microbiology and Infection. 2022;28(3):410-8.
33. Marciani DJ. Vaccine adjuvants: role and mechanisms of action in vaccine immunogenicity. Drug Discovery Today. 2003;8(20):934-43.
34. Iavarone C, O’hagan DT, Yu D, Delahaye NF, Ulmer JB. Mechanism of action of mRNA-based vaccines. Expert Review of Vaccines. 2017;16(9):871-81.
35. He P, Zou Y, Hu Z. Advances in aluminum hydroxide-based adjuvant research and its mechanism. Human Vaccines & Immunotherapeutics. 2015;11(2):477-88.
36. Ariamanesh M, Porouhan P, PeyroShabany B, Fazilat-Panah D, Dehghani M, Nabavifard M, et al. Immunogenicity and Safety of the Inactivated SARS-CoV-2 Vaccine (BBIBP-CorV) in Patients with Malignancy. Cancer Investigation. 2022;40(1):26-34.
37. Petrović V, Vuković V, Patić A, Marković M, Ristić MJPo. Immunogenicity of BNT162b2, BBIBP-CorV and Gam-COVID-Vac vaccines and immunity after natural SARS-CoV-2 infection—A comparative study from Novi Sad, Serbia. 2022;17(2):e0263468.
| Files | ||
| Issue | Vol 5, No 3 (2022) | |
| Section | Original Article | |
| DOI | https://doi.org/10.18502/igj.v5i3.16038 | |
| Keywords | ||
| COVID-19 Vaccines Hemodialysis Neutralizing Antibody SARS-CoV-2 | ||
| Rights and permissions | |
|
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License. |
How to Cite
1.
Khojasteh-Kaffash S, Jafari R, Fereidouni A, Fanoodi A, Raeesi V, Najafzadeh M, Fereidouni M. Immunogenicity of the Inactivated SARS-CoV-2 Vaccine (BBIBP-CorV) in Hemodialysis Patients: A Case-Control Study. Immunol Genet J. 2022;5(3):119-127.
